articleNature MedicineOct 1, 2022Closed access

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

JHJill HallinVBVickie BowcutACAndrew CalinisanDMDavid M. BriereLHLauren Hargis

Mirati Therapeutics (United States) · Pfizer (United States) · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

499
total citations
FWCI
37.68
Percentile
100%
References
49
Citations per year

Authors

30

Topics & keywords

Topics
Keywords
  • KRAS
  • Mutant
  • Cancer research
  • Cell culture
  • Biology
  • Chemistry
  • Mutation
  • Biochemistry
No related works found for this paper.